Akums Drugs and Pharmaceuticals Limited
₹731.90-₹9.20 (-1.2%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹6,983 Cr
- P/E
- 50.9x
- EV / EBITDA
- -133.2x
- Revenue
- ₹1,312 Cr
- Net margin
- -11.4%
- ROCE
- -30.7%
Price chart
Technical chartScreen technicals →+57.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -10.6%
- 3M
- +10.8%
- 6M
- +33.7%
- 1Y
- +57.0%
- 5Y
- -8.9%
52-week range
Day change -₹9.20 (-1.2%) from ₹741 to ₹732 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in AKUMS, bought on each weekday since 2024.
AI Summary
Indian StockStrengths1
- Valuation attractive — PE of 50.9x is 48% below peer average of 98.6x
Concerns1
- Negative free cash flow (₹368 Cr)
Rule-based from financial data. Not advice.
About the company
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds.
Read moreShow less
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.
- Sector
- Healthcare
- Shares outstanding
- 15.7 Cr shares
- ISIN
- INE09XN01023
- BSE code
- 544222
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹6,983 Cr
- P/E
- 50.9x
- P/B
- 2.9x
- EV / EBITDA
- -133.2x
- EV / Sales
- 4.8x
- P/S
- 4.8x
- Earnings yield
- 2.0%
- 52-week high
- ₹823.70
- 52-week low
- ₹414.30
Profitability
- Operating margin
- -8.7%
- Net margin
- -11.4%
- EBITDA margin
- -3.6%
- ROE
- -114.6%
- ROCE
- -30.7%
- ROA
- -7.9%
- Dividend payout
- 0.0%
- Tax rate
- 61.0%
- Other income, % of PBT
- -71.8%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,312 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -9.1%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.4%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹52.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -126.8%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -197.6%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹248 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 163.8%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹8.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.6%
Solvency and efficiency
- Current ratio
- 1.05
- Debt / Equity
- 1.85
- Debt / Assets
- 0.13
- Debt / EBITDA
- -5.13
- Financial leverage
- 14.55
- CFO / Net profit
- -1.50
- Cash / Market cap
- 23.4%
- Cash per share
- ₹103.70
- Asset turnover
- 0.69
- Fixed asset turnover
- 4.56
- Capital intensity
- 0.22
- Debtor days
- 59 days
- Inventory turnover
- 5.37
- Cash conversion cycle
- 58 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹12 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,177 Cr |
| Sales | Operating profit | ₹135 Cr |
| Operating profit | Interest | ₹15 Cr |
| Operating profit | Depreciation | ₹40 Cr |
| Operating profit | Profit before tax | ₹80 Cr |
| Other income | Profit before tax | ₹128 Cr |
| Profit before tax | Tax and other | ₹47 Cr |
| Profit before tax | Net profit | ₹161 Cr |
Revenue and net profit
Revenue fell 9.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹837 Cr | -₹145 Cr |
| FY2022 | ₹1,162 Cr | -₹382 Cr |
| FY2023 | ₹1,287 Cr | ₹125 Cr |
| FY2024 | ₹1,444 Cr | -₹165 Cr |
| FY2025 | ₹1,312 Cr | ₹161 Cr |
Cash flows
FY2025: ₹91.0 Cr from operations, -₹368 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹56 Cr | -₹44 Cr |
| FY2022 | ₹228 Cr | -₹70 Cr |
| FY2023 | ₹94 Cr | -₹108 Cr |
| FY2024 | ₹248 Cr | ₹83 Cr |
| FY2025 | ₹91 Cr | -₹368 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,312 Cr-9.1%1Y
- Net profit
- ₹161 Cr
- Cash from operations
- ₹91 Cr
- Free cash flow
- -₹368 Cr-543.4%1Y
- Revenue CAGR, 5Y
- 14.4%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,312 Cr | ₹135 Cr | — | ₹161 Cr | ₹91 Cr | -₹368 Cr | 7.0% | -9.1% | -197.6% |
Monthly returns
Month-by-month returns of AKUMS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,685 Cr |
| Equity capital | ₹31 Cr |
| Reserves | ₹2,275 Cr |
| Borrowings | ₹46 Cr |
| Other liabilities | ₹333 Cr |
| Assets | ₹2,685 Cr |
| Fixed assets | ₹356 Cr |
| Capital work in progress | ₹57 Cr |
| Investments | ₹366 Cr |
| Other assets | ₹1,906 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
AKUMS trades at 50.9x earnings against a peer median of 52.6x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals LimitedAKUMSthis company | ₹6,983 Cr | 50.9x | 2.9x | -114.6% | -133.2x |
| Marksans Pharma Ltd.MARKSANS | ₹7,873 Cr | 32.7x | 5.3x | 11.0% | 38.1x |
| Sudeep Pharma LimitedSUDEEPPHRM | ₹7,027 Cr | 73.5x | — | 29.3% | 49.9x |
| Aarti Pharmalabs LimitedAARTIPHARM | ₹6,923 Cr | 28.3x | 3.6x | 12.4% | 19.5x |
| PARK MEDI WORLD LIMITEDPARKHOSPS | ₹6,504 Cr | 906.0x | — | 7.0% | 214.8x |
| FDC Ltd.FDC | ₹6,387 Cr | 27.0x | 2.6x | 14.6% | 14.2x |
| YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITEDYATHARTH | ₹6,186 Cr | 67.3x | 3.9x | 10.0% | 45.5x |
| Kovai Medical Center & Hospital LtdKOVAI | ₹6,071 Cr | 26.6x | 5.1x | 20.2% | 17.2x |
| Supriya Lifescience LimitedSUPRIYA | ₹5,938 Cr | 32.6x | 5.5x | 14.6% | 31.4x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
AKUMS since 1 January, against earlier years.
Historical volatility
AKUMS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 3.0% |
| FY2022 | -31.0% |
| FY2023 | 19.0% |
| FY2024 | -9.0% |
| FY2025 | 10.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,312 Cr |
| Costs | |
| Interest | ₹15 Cr |
| Expenses | ₹1,177 Cr |
| Operating profitOperating Profit | ₹135 Cr |
| Other income and charges | |
| Profit before tax | ₹208 Cr |
| Tax | |
| Net profitNet Profit | ₹161 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,685 Cr |
| Equity capitalEquity Capital | ₹31 Cr |
| Reserves | ₹2,275 Cr |
| Borrowings | ₹46 Cr |
| Other liabilitiesOther Liabilities | ₹333 Cr |
| AssetsTotal Assets | ₹2,685 Cr |
| Fixed assetsFixed Assets | ₹356 Cr |
| Capital work in progressCWIP | ₹57 Cr |
| Investments | ₹366 Cr |
| Other assetsOther Assets | ₹1,906 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹91 Cr |
| Investing cash flowCash from Investing Activity | -₹459 Cr |
| Financing cash flowCash from Financing Activity | ₹375 Cr |
| Change in cashNet Cash Flow | ₹8 Cr |
Learn while you research
Academy chapters picked for Akums Drugs and Pharmaceuticals Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 50.9, learn when high multiples are justified.6 min read
- 04 Leverage RatiosDebt/Equity of 1.85 is elevated, understand what that means for solvency.6 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read